Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 206,535 | 273,721 | 35,482 | 59,150 | 20,291 |
| Marketable Securities | 187,720 | 165,057 | 178,362 | 177,215 | 115,194 |
| TOTAL | $403,802 | $447,659 | $224,071 | $242,720 | $138,073 |
| Non-Current Assets | |||||
| PPE Net | 465 | 453 | 626 | 729 | 701 |
| Investments And Advances | 21,932 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 8,487 | 2,936 | 1,953 | 1,870 | 3,078 |
| TOTAL | $30,884 | $3,389 | $2,579 | $2,599 | $3,779 |
| Total Assets | $434,686 | $451,048 | $226,650 | $245,319 | $141,852 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,828 | 2,731 | 4,589 | 1,633 | 1,096 |
| Accrued Expenses | 21,326 | 5,835 | 4,838 | 5,565 | 14,345 |
| Other current liabilities | 10,000 | N/A | N/A | N/A | N/A |
| TOTAL | $36,843 | $19,666 | $17,894 | $46,500 | $15,441 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 104,091 | 99,248 | N/A | N/A |
| Deferred Revenues | 1,689 | 1,632 | 1,632 | 33,733 | N/A |
| Other Non-Current Liabilities | 104,487 | 0 | 1,100 | 94,630 | 90,257 |
| TOTAL | $105,587 | $105,191 | $100,348 | $94,630 | $90,257 |
| Total Liabilities | $142,430 | $124,857 | $118,242 | $141,130 | $105,698 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 114,724 | 113,403 | 98,150 | 97,513 | 97,293 |
| Common Shares | 11 | 18 | 17 | 17 | 8 |
| Retained earnings | -978,227 | -936,325 | -902,443 | -901,635 | -872,857 |
| Other shareholders' equity | 144 | -62 | -124 | -70 | -326 |
| TOTAL | $292,256 | $326,191 | $108,408 | $104,189 | $36,154 |
| Total Liabilities And Equity | $434,686 | $451,048 | $226,650 | $245,319 | $141,852 |